Baxter's Q3 Sales Fall Short of Expectations
Baxter (NYSE: BAX) shares declined after the company's third-quarter results failed to meet Wall Street's sales forecast.
Shares of BAX fell over 16% to $18.82 in early trading, with the company reporting a net loss of $46 million, or 9¢ per share, on sales of $2.84 billion.
- Sales increased 5% from the same period last year.
- Adjusted earnings per share were 69¢, exceeding expectations by 9¢.
- Medical Products & Therapies sales were $1.33 billion, a 1% decline.
No comment from the company on the sales miss.
Author's summary: Baxter's Q3 sales missed expectations.
More News
- Rediscovery of African American burial grounds provides long-overdue opportunities for collective healing
- Just 2-in-5 Chicago students read at grade level under lowered proficiency standards
- Why A-list celebrities are heading to Macao this season
- Meyn expands US footprint with US$65 million investment in new manufacturing & innovation campus
- SCHGS receives regional grant
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men
- Flau’jae Johnson Shuts Down Governor’s Call for Charlie Kirk Statue at LSU, Social Media Rides With Her
- How Artissima’s Curatorial and Institutional DNA Sets It Apart from the Mega-Fairs
- Why Israel Lost the Gaza Opinion War
- Am I self-aware or just chronically online?